Autori: De Sanctis R*

Filtra

Data

Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome?

Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3

Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA.

Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module

Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016

Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded

Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study

Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data

Early treatment of type II SMA slows rate of progression of scoliosis

Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na‹ve patients with spinal muscular atrophy and following switch from other therapies

Torna in alto